TEK and neoplasm: In oncology, targeting the Ang/Tie2 pathway remains biologically compelling but clinically mixed: Ang-2 promotes vascular destabilization, hypoxia, and recruitment of pro-metastatic Tie2-high macrophages, while Tie2 activation can normalize tumor vessels, improving perfusion and drug delivery.